79714-31-1
基本信息
RISARESTAT (CT-112)
CT 112 (reductase inhibitor)
5-(3-Ethoxy-4-pentoxyphenyl)thiazolidine-2,4-dione
5-(3-Ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione
5-[3-Ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione
2,4-Thiazolidinedione, 5-[3-ethoxy-4-(pentyloxy)phenyl]-
物理化学性质
| 沸点 | 485.9±45.0 °C(Predicted) |
| 密度 | 1.189±0.06 g/cm3(Predicted) |
| 酸度系数(pKa) | 5.91±0.50(Predicted) |
| 形态 | Solid |
| 颜色 | White to light yellow |
RISARESTAT价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-16433 | Risarestat | 79714-31-1 | 1 mg | 1800元 |
| 2025/05/22 | HY-16433 | RISARESTAT Risarestat | 79714-31-1 | 5mg | 4300元 |
| 2025/05/22 | HY-16433 | Risarestat | 79714-31-1 | 10 mM * 1 mLin DMSO | 4730元 |
常见问题列表
Risarestat inhibits the accumulation of dulcitol in a dose-dependent manner, except for the 1.0% solution which has an activity comparable to the 0.25% solution. Risarestat peaks in the corneal epithelium, stroma, endothelium and aqueous humor in 30 minutes following instillation, then gradually diminishes time-dependently over a period of 24 hours. Risarestat remains detectable in the lens up to 24 hours, with a peak concentration at 2 hours after instillation. The anterior surface area of superficial cells in the group treated with Risarestat is significantly decreases from a mean value of 881 to 728 microns 2 . Corneal sensitivity significantly improves from 5.36 to 1.37 g/mm 2 . Animals treated with Risarestat shows a significant increase in the mean blinkresponse compared to untreated galactose-fed rats and does not differ significantly from controls towards the completion of the 7 month study. Animals treated topically with Risarestat and untreated galactose-fed rats develop bilateral nuclear cataracts within 3 weeks.